Name: UMIN ID:
Unique ID issued by UMIN | UMIN000005428 |
---|---|
Receipt number | R000005907 |
Scientific Title | Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. |
Date of disclosure of the study information | 2011/04/12 |
Last modified on | 2020/04/19 17:21:01 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2011/04/12 22:52:29 | ||
2 | Update | 2020/04/19 17:03:18 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code TEL Last name of contact person Last name of contact person Zip code TEL Name of primary person or sponsor Organization Post marketing survey by drug manufacture etc., specified by Japanese law. Organization Organization Address Address Tel |
|
3 | Update | 2020/04/19 17:06:34 | Date of IRB Last follow-up date |
|
4 | Update | 2020/04/19 17:21:01 | Last follow-up date |